{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dovitinib+lactate", "query": { "intervention": "dovitinib lactate" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dovitinib+lactate&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-22T02:31:26.993Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01700270", "title": "Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors, Excluding Breast Cancer" ], "interventions": [ { "name": "dovitinib (TKI258)", "type": "DRUG" }, { "name": "fluvoxamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2013-05", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2020-12-21", "last_synced_at": "2026-09-22T02:31:26.993Z", "location_count": 2, "location_summary": "The Bronx, New York • San Antonio, Texas", "locations": [ { "city": "The Bronx", "state": "New York" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01700270" }, { "nct_id": "NCT01443481", "title": "Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Hepatic Impairment" ], "interventions": [ { "name": "Dovitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2011-11", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2020-12-21", "last_synced_at": "2026-09-22T02:31:26.993Z", "location_count": 3, "location_summary": "Los Angeles, California • Durham, North Carolina • San Antonio, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Durham", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01443481" }, { "nct_id": "NCT01888965", "title": "Maintenance Dovitinib for Colorectal and Pancreas Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Pancreas Cancer" ], "interventions": [ { "name": "Dovitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2013-10", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2016-07-19", "last_synced_at": "2026-09-22T02:31:26.993Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01888965" }, { "nct_id": "NCT01528345", "title": "Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Dovitinib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Dovitinib Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 97, "start_date": "2012-04", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-07-11", "last_synced_at": "2026-09-22T02:31:26.993Z", "location_count": 18, "location_summary": "Chandler, Arizona • Fayetteville, Arkansas • Duarte, California + 15 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01528345" }, { "nct_id": "NCT01223027", "title": "Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "Dovitinib", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 564, "start_date": "2011-03", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2015-12-07", "last_synced_at": "2026-09-22T02:31:26.993Z", "location_count": 34, "location_summary": "Fayetteville, Arkansas • La Jolla, California • Los Angeles, California + 26 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01223027" }, { "nct_id": "NCT00958971", "title": "Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "TKI258", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 43, "start_date": "2009-07", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-09-22T02:31:26.993Z", "location_count": 18, "location_summary": "Bakersfield, California • Beverly Hills, California • Los Angeles, California + 13 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redondo Beach", "state": "California" }, { "city": "Santa Maria", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00958971" }, { "nct_id": "NCT01515969", "title": "Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC), Recurrent", "Non-small Cell Lung Cancer (NSCLC), Stage IV" ], "interventions": [ { "name": "Erlotinib hydrochloride", "type": "DRUG" }, { "name": "Dovitinib lactate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Heather Wakelee", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2012-07", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2016-07-12", "last_synced_at": "2026-09-22T02:31:26.993Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01515969" }, { "nct_id": "NCT00831792", "title": "TKI258 in Castrate Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "TK1258", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 46, "start_date": "2010-04-07", "completion_date": "2017-06-12", "has_results": true, "last_update_posted_date": "2019-09-11", "last_synced_at": "2026-09-22T02:31:26.993Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00831792" }, { "nct_id": "NCT01496534", "title": "Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Bladder Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Matthew Galsky", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2012-01", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2013-11-27", "last_synced_at": "2026-09-22T02:31:26.993Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01496534" }, { "nct_id": "NCT00715182", "title": "A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/ Metastatic Renal Cell Cancer" ], "interventions": [ { "name": "TKI258", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2008-07", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2020-12-21", "last_synced_at": "2026-09-22T02:31:26.993Z", "location_count": 3, "location_summary": "San Francisco, California • Durham, North Carolina • Seattle, Washington", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00715182" } ] }